Dumitru Cravcenco
Research Subjects
Research Interests
Dumitru Cravcenco has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alexandr Ceasovschih
Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
2 shared publications - Alexandru Corlateanu
Department of Respiratory Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova
2 shared publications - Ecaterina Iavrumov
State University of Medicine and Pharmacy “Nicolae Testemitanu”, Department of Respiratory Medicine and allergology, Chisinau, Republic of Moldova
2 shared publications - Nikolaos Siafakas
Clinical Microbiology Laboratory, “Attikon” University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
2 shared publications - Pradeesh Sivapalan
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen
2 shared publications Feodor Ostopovici
1 shared publication
Latest Publications
- Open Access
- 12 September 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (12) , 6110-6114
Reversed intestinal malrotation with volvulus in an adult: A case report
- 12 September 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (12) , 6110-6114
Open AccessReversed intestinal malrotation with volvulus in an adult: A case report
- Open Access
- 19 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 785
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography (HRCT) has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aimed to explore the impact of chest computed tomography (CT) imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, the median age of the study population was 70.0 years (Q1–Q3: 62.0–75.0); 86% were men (85), and 14% were women (14). All patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification (ABE groups), 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections, and 3% for interstitial abnormalities. In 4%, there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusions: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients may contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- 19 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 785
Open AccessAssessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography (HRCT) has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aimed to explore the impact of chest computed tomography (CT) imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, the median age of the study population was 70.0 years (Q1–Q3: 62.0–75.0); 86% were men (85), and 14% were women (14). All patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification (ABE groups), 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections, and 3% for interstitial abnormalities. In 4%, there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusions: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients may contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- Open Access
- 4 January 2026
- Published by MDPI AG in Preprints.org
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aims to explore the impact of chest CT imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, with an average age of 67,8 (37-88), 86% were men (85), and 14% were women (14). The patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification, ABE type, 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections and 3% for interstitial abnormalities. In 4% there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusion: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients can contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.
- 4 January 2026
- Published by MDPI AG in Preprints.org
Open AccessAssessment of Comorbidities in Chronic Obstructive Pulmonary Disease Patients by Chest High Resolution Computed Tomography (HRCT)
Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. High resolution computed tomography has emerged as a valuable tool for diagnosing and managing COPD-related comorbidities. This study aims to explore the impact of chest CT imaging in identifying and characterizing comorbidities in COPD patients. Methods: The study was conducted on 99 patients with COPD, with an average age of 67,8 (37-88), 86% were men (85), and 14% were women (14). The patients underwent chest HRCT to identify the presence of comorbidities. Results: According to the GOLD classification, ABE type, 3% were type A, 27% were type B, and 69% were type E. The prevalence of comorbidities identified on chest HRCT was reported as 66% for coronary artery calcification (CAC), 83% for osteoporosis, 36% for pulmonary artery enlargement (PAE), 31% for emphysema, 19% for bronchiectasis, 17% for hiatal hernia, 14% for lung cancer, 12% pulmonary infections and 3% for interstitial abnormalities. In 4% there were no comorbidities, one comorbidity was found in 11%, two comorbidities in 17%, and three comorbidities and more in 68% of cases. Conclusion: Chest HRCT imaging serves as a valuable tool for identifying and assessing comorbidities in patients with COPD. Incorporating chest CT imaging into the routine evaluation of COPD patients can contribute to a more comprehensive understanding of their condition and lead to better clinical outcomes.